Colon cancer subtypes: concordance, effect on survival and selection of the most representative preclinical models
Author:
Publisher
Springer Science and Business Media LLC
Subject
Multidisciplinary
Link
http://www.nature.com/articles/srep37169.pdf
Reference46 articles.
1. Heinemann, V., Douillard, J. Y., Ducreux, M. & Peeters, M. Targeted therapy in metastatic colorectal cancer – an example of personalised medicine in action. Cancer treatment reviews 39, 592–601, doi: 10.1016/j.ctrv.2012.12.011 (2013).
2. Yamauchi, M. et al. Colorectal cancer: a tale of two sides or a continuum? Gut 61, 794–797, doi: 10.1136/gutjnl-2012-302014 (2012).
3. Cancer Genome Atlas, N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337, doi: 10.1038/nature11252 (2012).
4. Amado, R. G. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26, 1626–1634, doi: 10.1200/JCO.2007.14.7116 (2008).
5. Vaughn, C. P., Zobell, S. D., Furtado, L. V., Baker, C. L. & Samowitz, W. S. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes, chromosomes & cancer 50, 307–312, doi: 10.1002/gcc.20854 (2011).
Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The evolution and prospects of the gene expression profiling in colorectal cancer;Journal of Clinical and Scientific Research;2023
2. Transcriptomic and Cellular Content Analysis of Colorectal Cancer by Combining Multiple Independent Cohorts;Clinical and Translational Gastroenterology;2022-07-20
3. Identification of Synergistic Drug Combinations to Target KRAS-Driven Chemoradioresistant Cancers Utilizing Tumoroid Models of Colorectal Adenocarcinoma and Recurrent Glioblastoma;Frontiers in Oncology;2022-05-18
4. The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer;Journal of Experimental & Clinical Cancer Research;2022-03-29
5. Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer;Nature Communications;2022-02-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3